Prabhudas Lilladher's research report on Rainbow Childrens Medicare
RAINBOW’s Q2FY26 was weak quarter with EBITDA grew by mere 1% YoY to Rs1.5bn. RAINBOW enjoys higher margins, strong FCF generation with net cash B/S, and healthy return ratios because of the asset-light hub-and-spoke model, it being the only integrated multi-specialty pediatric hospital chain in India offering comprehensive services, and its full-time doctor engagement model. Strategic expansion across its core markets in South India also augurs well for its sustainable growth. Our FY26E / FY27E EBITDA stands reduced by ~10% as we factor in lower occupancy.
Outlook
Overall, we see profitability to improve from FY27 with 19% EBITDA CAGR over FY26-28E vs 10% CAGR over FY24-26E as new capacities ramp up. Maintain ‘BUY’ rating with revised TP of Rs1,600/share valuing at 27x EV/EBITDA based on pre-IndAS Sept 2027E EBITDA.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
